Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Covington
Healthtrust
Julphar
Queensland Health
Baxter
Accenture
Colorcon
Cipla

Generated: April 22, 2018

DrugPatentWatch Database Preview

BEXAROTENE Drug Profile

« Back to Dashboard

When do Bexarotene patents expire, and when can generic versions of Bexarotene launch?

Bexarotene is a drug marketed by Bionpharma Inc and is included in one NDA.

The generic ingredient in BEXAROTENE is bexarotene. There are seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the bexarotene profile page.
Drug patent expirations by year for BEXAROTENE
Pharmacology for BEXAROTENE
Ingredient-typeRetinoids
Drug ClassRetinoid
Synonyms for BEXAROTENE
153559-49-0
166175-31-1
3-methyl-TTNEB
4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid
4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl)benzoic acid
4-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic acid
4-[1-(1,1,4,4,7-pentamethyltetralin-6-yl)vinyl]benzoic acid
4-[1-(3,5,5,8,8-Pentamethyl-2-5,8-dihydronaphthyl)vinyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-vinyl]-benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-vinyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-vinyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid
4-[1-(5,6,7,8-TETRAHYDRO-3,5,5,8,8-PENTAMETHYL-2-N
4-[1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-1-ethenyl]benzoic acid
4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]benzoic acid
4-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl]benzoic acid
4-[1-3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthaleneyl)vinyl]benzene carboxylic acid
42161-EP2295426A1
42161-EP2295427A1
42161-EP2298768A1
42161-EP2308861A1
42161-EP2311808A1
42161-EP2311829A1
42161-EP2311840A1
4k6i
559B490
9RA
A61RXM4375
A809441
AB0009892
AB01275475_02
AB01275475-01
AB2000502
AC-24569
AC1L32UG
ACT03911
AJ-26838
AK-64115
AKOS015902814
AN-616
AOB1247
AT-22934
BCP0726000106
BCP9000396
BDBM50032675
Benzoic acid, 4-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)-
Benzoic acid,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]-
Bexaroten
Bexarotene (JAN/USAN/INN)
Bexarotene (USAN/INN)
Bexarotene [USAN:INN:BAN]
Bexarotene [USAN]
Bexarotene oral(targretin)
Bexarotene, >=98% (HPLC)
bexaroteno
bexarotenum
BG0619
BIDD:PXR0021
CAS-153559-49-0
CCG-221823
CHEBI:50859
CHEMBL1023
CS-0626
CTK8E7385
D03106
D0N0RU
DB00307
DL-298
DSSTox_CID_20619
DSSTox_GSID_40619
DSSTox_RID_79514
DTXSID1040619
Elan brand of bexarotene
FT-0657110
FT-0702645
GTPL2807
HMS2089L14
HMS3655D19
HSDB 7453
HY-14171
I14-1941
J-009026
J-519847
KB-188553
KS-00000NW6
LG 100069
LG 1069
LG 69
LG-100069
LG100069
LG1069
LG69 compound
LGD 1069
LGD-1069
LGD1069
Ligand brand of bexarotene
LS-38306
MCULE-3783114634
MFCD00932428
MLS006010146
MolPort-003-845-030
NAVMQTYZDKMPEU-UHFFFAOYSA-N
NCGC00181016-01
NCGC00181016-02
NCGC00181016-03
NCGC00181016-04
NCGC00255426-01
NSC-747528
NSC747528
OR069389
OR126219
OR126220
OR224989
p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid
p-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl]benzoic acid
QCR-117
RL01964
Ro 26-4455
RTX-011348
s2098
SBB067189
SC-19638
SC-50515
SCHEMBL9025
SMR001614557
SR 11247
SR-05000001480
SR-05000001480-2
SS-4628
ST24046138
Targret
Targretin
Targretin (TN)
Targretin-gel
Targretyn
Targrexin
Tox21_112666
Tox21_112666_1
Tox21_302407
UNII-A61RXM4375
W-5228
ZINC1539579

US Patents and Regulatory Information for BEXAROTENE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bionpharma Inc BEXAROTENE bexarotene CAPSULE;ORAL 203174-001 Aug 12, 2014 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Covington
Fuji
Express Scripts
Moodys
Johnson and Johnson
US Department of Justice
Argus Health
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.